Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3

Molecular Imaging

Volumn 12, Issue 1, 2013, Pages 39-48

  Shao, Guoqiang ^b   Zhou, Yang ^b   Wang, Feng ^b   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; BIODISTRIBUTIONS; EXPRESSION LEVELS; GLIOMA CELLS; IMAGING TOOLS; IMMUNOHISTOCHEMISTRY; INTEGRINS; NETHERLANDS; QUADRATIC POLYNOMIAL; SCREENING TOOL; SPECT/CT; TUMOR DETECTION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR SIZE; TUMOR UPTAKE; TUMOR VOLUMES;

BLOOD VESSELS; CURVE FITTING; PATIENT TREATMENT; SCANNING; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMORS;

DIAGNOSIS;

CYCLOPEPTIDE; TECHNETIUM 99M (HYNIC 3PRGD(2))(TRICINE)(TPPTS); TECHNETIUM 99M (HYNIC-3PRGD(2))(TRICINE)(TPPTS); TECHNETIUM COMPLEX; VITRONECTIN RECEPTOR;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BRAIN TUMOR; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; FEMALE; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOUSE; NECROSIS; NUDE MOUSE; PATHOLOGY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; LIMIT OF DETECTION; MICE; MICE, NUDE; MOLECULAR IMAGING; NECROSIS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

MLCS; MLOWN;

EID: 84873914066     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2012.00019     Document Type: Article

References (53)

1. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33, doi:10.1101/gad.891601.
2. Steiner HH, Karcher S, Mueller MM, et al. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004;66:129-38, doi:10.1023/B:NEON. 0000013495.08168.8f.
3. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009;92:317-35, doi:10.1007/s11060-009-9827-2.
4. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-58.
5. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res 2004;117:249-62, doi:10.1007/978-1-4419-8871-3-15.
6. Pierallini A, Bonamini M, Pantano P, et al. Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology 1998;40:150-3, doi:10.1007/s002340050556.
7. Hammoud MA, Sawaya R, Shi W, et al. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996;27:65-73, doi:10.1007/BF00146086.
8. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8, doi:10.3171/jns.2001.95.2.0190.
9. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22, doi:10.1038/nrn2175.
10. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22, doi:10.1038/nrc2748.
11. 5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-9.
12. Smythe WR, LeBel E, Bavaria JE, et al. Integrin expression in non-small cell carcinoma of the lung. Cancer Metastasis Rev 1995;14: 229-39, doi:10.1007/BF00690294.
13. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc-amplifica-tion, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
14. 3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57:1554-60.
15. 3 integrin receptors in breast tumor. J Exp Clin Cancer Res 2001;20:585-90.
16. Reardon DA, Turner S, Peters KB, et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 2011;9:414-27.
17. Paulus W, Baur I, Schuppan D, Roggendorf W. Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 1993;143:154-63.
18. 3 directed radiopharmaceuticals for tumor imaging. Drugs Future 2003;28: 551-64, doi:10.1358/dof.2003.028.06.740860.
19. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439-55, doi:10.2174/1381612043384745.
20. D'Andrea LD, Del Gatto A, Pedone C, Benedetti E. Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006;67:115-26, doi:10.1111/j.1747-0285. 2006.00356.x.
21. Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 2001;39: 155-71, doi:10.1016/S1040-8428(01)00115-9.
22. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008;17:1225-35, doi:10.1517/13543784.17.8.1225.
23. 3 antagonists. J Am Chem Soc 1996;118:7461-72, doi:10.1021/ja9603721.
24. 3 integrin antagonists. J Med Chem 1999;42:3033-40, doi:10.1021/jm970832g.
25. 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003;6:105-19, doi:10.1023/B:AGEN.0000011801.98187.f2.
26. Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006;59:1304-12, doi:10.1227/01.NEU. 0000245622.70344.BE.
27. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.
28. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-7, doi:10.1200/JCO.2006.06.6514.
29. O'Donnell PH, Undevia SD, Stadler WM, et al. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs 2012;30:604-10. Epub 2010 Sep 14.
30. Reardon D, Fink K, Nabors B, et al. Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. J Clin Oncol 2007;25: 2002.
31. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-7, doi:10.1200/JCO.2008.16.7510.
32. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblas-toma (GBM). J Clin Oncol 2007;25:2000, doi:10.1200/JCO. 2006.10.1386.
33. Friess H, Langrehr JM, Oettle H, et al. A randomized multicenter phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006;6:285, doi:10.1186/1471-2407-6-285.
34. 18F]Galacto-RGD. PLoS Med 2005;2:e70, doi:10.1371/journal.pmed.0020070.
35. 18F-Galacto-RGD PET. J Nucl Med 2008;49:255-9, doi:10.2967/jnumed.107.045526.
36. 18F] Galacto-RGD positron emission tomography. Neurooncol 2009;11:861-70.
37. 4 linkers. Mol Pharm 2009;6:231-45, doi:10.1021/mp800150r.
38. 2 in non-human primates. Mol Imaging Biol 2011;13:730-6, doi:10.1007/s11307-010-0385- y.
39. 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009;20:2199-213, doi:10.1021/bc900167c.
40. 2 scintigraphy. Eur J Nucl Med Mol Imaging 2011;38:2145-52, doi:10.1007/s00259-011-1901-2.
41. 3 expression. Mol Imaging 2011;10:386-97.
42. The National Institutes of Health. Principles of laboratory animal care. Bethesda (MD): National Institutes of Health; 1985. NIH publication no.: 86-23.
43. Vaneycken I, Govaert J, Vincke C, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 2010;51:1099-106, doi:10.2967/jnumed.109.069823.
44. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23, doi:10.1056/NEJM200101113440207.
45. 3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008;18:378-86, doi:10.1111/j.1750-3639. 2008.00137.x.
46. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
47. Michalski MH, Chen X. Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging 2011;38:358-77, doi:10.1007/s00259-010-1569-z.
48. Wang J, Chen LT, Tsang YM, et al. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 2004;183:713-9.
49. Palmowski M, Schifferdecker I, Zwick S, et al. Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. Eur J Radiol 2010;74: e176-80, doi:10.1016/j.ejrad. 2009.05.042.
50. Kaijzel EL, van der Pluijm G, Löwik CW. Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res 2007;13:3490-7, doi:10.1158/1078-0432.CCR-07-0402.
51. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
52. Zhao D, Richer E, Antich PP, Mason RP. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. FASEB J 2008;22:2445-51, doi:10.1096/fj.07-103713.
53. Raza SM, Lang FF, Aggarwal BB, et al. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002;51: 2-12, doi:10.1097/00006123-200207000-00002.